UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Clinical cancer research, 2020-08, Vol.26 (16), p.4280-4288

2020

Volltextzugriff (PDF)

FDA Approval: Blinatumomab

Clinical cancer research, 2015-09, Vol.21 (18), p.4035-4039

2015

Volltextzugriff (PDF)

FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease

The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.e328-e334

2020

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Clinical cancer research, 2013-09, Vol.19 (17), p.4559-4563

2013

Volltextzugriff (PDF)

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Journal of clinical oncology, 2022-03, Vol.40 (8), p.847-854

2022

Volltextzugriff (PDF)

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

Clinical cancer research, 2020-01, Vol.26 (2), p.328-331

2020

Volltextzugriff (PDF)

Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

Leukemia, 2020-11, Vol.34 (11), p.3082-3084

2020

Volltextzugriff (PDF)

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2078-2085

2007

Volltextzugriff (PDF)

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

Clinical cancer research, 2019-01, Vol.25 (2), p.473-477

2019

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Clinical cancer research, 2019-06, Vol.25 (11), p.3205-3209

2019

Volltextzugriff (PDF)

Vector Targeting Makes 5-Fluorouracil Chemotherapy Less Toxic and More Effective in Animal Models of Epithelial Neoplasms

Clinical cancer research, 2004-11, Vol.10 (22), p.7738-7746

2004

Volltextzugriff (PDF)

Genetic Systems for the Diagnosis and Treatment of Human Disease

Cancer biology & therapy, 2004-01, Vol.3 (1), p.126-131

Deisseroth, Albert

2004

Volltextzugriff (PDF)

Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon

Cancer gene therapy, 2003-05, Vol.10 (5), p.388-395

2003

Volltextzugriff (PDF)

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Clinical cancer research, 2015-03, Vol.21 (5), p.950-954

2015

Volltextzugriff (PDF)

Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer

Molecular cancer therapeutics, 2006-08, Vol.5 (8), p.1975-1985

2006

Volltextzugriff (PDF)

Acute Myeloid Leukemia Response Measures Other Than Complete Remission

Journal of clinical oncology, 2015-11, Vol.33 (31), p.3675-3676

2015

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

Clinical cancer research, 2012-06, Vol.18 (12), p.3212-3217

2012

Volltextzugriff (PDF)

International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers

Cancer Immunology, Immunotherapy, 2006-11, Vol.55 (11), p.1406-1411

2006

Volltextzugriff (PDF)

Peptides Inhibitory for the Transcriptional Regulatory Function of Human Papillomavirus E2

Clinical cancer research, 2003-11, Vol.9 (14), p.5423-5428

2003

Volltextzugriff (PDF)

U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission

The oncologist (Dayton, Ohio), 2019-05, Vol.24 (5), p.e188-e195

2019

Volltextzugriff (PDF)

Gemtuzumab ozogamicin

Journal of clinical oncology, 2013-05, Vol.31 (13), p.1699-1700

2013

Volltextzugriff (PDF)

Determination of Similarity Margin in Comparative Clinical Studies to Support the Development of Biosimilar Products of Neupogen® (Filgrastim, Granulocyte Colony-Stimulating Factor [G-CSF])

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2018-08, Vol.32 (4), p.325-330

2018

Volltextzugriff (PDF)

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Clinical cancer research, 2017-11, Vol.23 (22), p.6759-6763

2017

Volltextzugriff (PDF)

Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.655-666

2007

Volltextzugriff (PDF)

Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells

Cancer gene therapy, 1999-03, Vol.6 (2), p.99-106

1999

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(78)

Sprache

Englisch
(78)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(78)
Science & Technology
(78)
Humans
(68)
Female
(36)
Middle Aged
(30)
Biological And Medical Sciences
(28)
Male
(28)
Adult
(27)
Medical Sciences
(26)
Aged
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Animals
(15)
Combined Modality Therapy
(12)
Pharmacology. Drug Treatments
(12)
Antineoplastic Agents
(11)
Adolescent
(10)
Cancer Research
(9)
Hematopoietic Stem Cell Transplantation
(9)
Remission Induction
(9)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

FDA Approval: Blinatumomab

FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Vector Targeting Makes 5-Fluorouracil Chemotherapy Less Toxic and More Effective in Animal Models of Epithelial Neoplasms

Genetic Systems for the Diagnosis and Treatment of Human Disease

Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer

Acute Myeloid Leukemia Response Measures Other Than Complete Remission

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers

Peptides Inhibitory for the Transcriptional Regulatory Function of Human Papillomavirus E2

U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission

Gemtuzumab ozogamicin

Determination of Similarity Margin in Comparative Clinical Studies to Support the Development of Biosimilar Products of Neupogen® (Filgrastim, Granulocyte Colony-Stimulating Factor [G-CSF])

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells

Aktive Filter

Suchergebnisse filtern